

Spotlight on mCRC

FOSTERING COMMUNITY
TO ADVANCE PATIENT CARE

Welcome to the second edition of Spotlight on mCRC with:
Real-world experiences in mCRC

THURSDAY, 25TH SEPTEMBER 2025
17:00-19:00 CEST - STREAMED ONLINE

REGISTER NOW!



Chaired by

JULIEN TAIEB

Head of the Gastroenterology and Gastrointestinal Oncology Department
Hôpital Européen Georges-Pompidou, Université de Paris, France



FACULTY

The Value of Real-World Evidence in mCRC

MIRIAM KOOPMAN

University Medical Center Utrecht
Utrecht,
Netherlands

ELENA ÉLEZ

Vall d'Hebron Institute of Oncology
Barcelona,
Spain

MICHAEL NEUMAIER

Universitätsmedizin Mannheim Institut für Klinische Chemie
Mannheim,
Germany

Clinical Cases in mCRC and Best Practices

MARTINA AMNITZBØLL ERIKSEN

Rigshospitalet
Copenhagen,
Denmark

SÉRGIO XAVIER AZEVEDO

Faculdade de Medicina da Universidade do Porto
Porto,
Portugal

IOANNIS SOUGLAKOS

University of Crete
Crete,
Greece

AGENDA

The Value of Real-World Evidence in mCRC

Welcome and Introduction

How should real-world data from mCRC make a difference?

Real-world insights into the treatment of specific mCRC alterations

Using molecular biomarkers in the real world: Trends and challenges

Julien Taieb, Andrea Grignolio

Miriam Koopman

Elena Élez

Michael Neumaier

Clinical Cases in mCRC and Best Practices

Opening and overview of the clinical cases

A patient with *BRAF*^{V600E}-mutant and MSI-H mCRC

A patient with *KRAS*^{G12C}-mutant mCRC

A patient with HER2 overexpression

Julien Taieb

Martina Amnitzbøll Eriksen

Sérgio Xavier Azevedo

Ioannis Souglakos

Q&A Session & Closing



LABORATOIRES

Pierre Fabre

Innovative Oncology

Spotlight

on

mCRC

FOSTERING COMMUNITY
TO ADVANCE PATIENT CARE

Welcome to the second edition of Spotlight on mCRC with: Real-world experiences in mCRC

THURSDAY, 25TH SEPTEMBER 2025
17:00-19:00 CEST - STREAMED ONLINE

Chaired by

JULIEN TAIEB

Head of the Gastroenterology and Gastrointestinal Oncology Department
Hôpital Européen Georges-Pompidou, Université de Paris, France



FACULTY

The Value of Real-World Evidence in mCRC

MIRIAM KOOPMAN

University Medical Center Utrecht
Utrecht,
Netherlands

ELENA ÉLEZ

Vall d'Hebron Institute of Oncology
Barcelona,
Spain

MICHAEL NEUMAIER

Universitätsmedizin Mannheim Institut für Klinische Chemie
Mannheim,
Germany

Clinical Cases in mCRC and Best Practices

MARTINA AMNITZBØLL ERIKSEN

Rigshospitalet
Copenhagen,
Denmark

SÉRGIO XAVIER AZEVEDO

Faculdade de Medicina da Universidade do Porto
Porto,
Portugal

IOANNIS SOUGLAKOS

University of Crete
Crete,
Greece

AGENDA

The Value of Real-World Evidence in mCRC

Welcome and Introduction

How should real-world data from mCRC make a difference?

Real-world insights into the treatment of specific mCRC alterations

Using molecular biomarkers in the real world: Trends and challenges

Julien Taieb, Andrea Grignolio

Miriam Koopman

Elena Élez

Michael Neumaier

Clinical Cases in mCRC and Best Practices

Opening and overview of the clinical cases

A patient with *BRAF*^{V600E}-mutant and MSI-H mCRC

A patient with *KRAS*^{G12C}-mutant mCRC

A patient with HER2 overexpression

Julien Taieb

Martina Amnitzbøll Eriksen

Sérgio Xavier Azevedo

Ioannis Souglakos

Q&A Session & Closing



LABORATOIRES
Pierre Fabre
Innovative Oncology